Education
About Us
Working with TipRanks
Follow Us
Joint Corp (JYNT)
:JYNT
JYNT Stock Chart & Stats
$8.46
$0.12(1.11%)
At close: 4:00 PM EST
$8.46
$0.12(1.11%)
Day’s Range― - ―
52-Week Range$7.50 - $13.47
Previous CloseN/A
Volume11.07K
Average Volume (3M)115.37K
Market Cap
$125.77M
Enterprise Value$118.31M
Total Cash (Recent Filing)$30.71M
Total Debt (Recent Filing)$2.09M
Price to Earnings (P/E)66.9
Beta1.07
Next Earnings
Mar 05, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding14,866,192
10 Day Avg. Volume182,090
30 Day Avg. Volume115,366
Financial Highlights & Ratios
PEG Ratio1.36
Price to Book (P/B)8.85
Price to Sales (P/S)3.06
P/FCF Ratio19.27
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue81.93
Enterprise Value/Gross Profit-11.70
Enterprise Value/Ebitda-82.55
Forecast
1Y Price Target
$11.33Price Target Upside33.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)0.04
Revenue Forecast (FY)$54.77M
Bulls Say, Bears Say
Bulls Say
Cost ManagementJYNT's gross margin was above consensus and estimates, indicating effective cost management.
Franchise TransitionJYNT reached an agreement to sell 45 corporate clinics, advancing its transition to a full franchise model.
Net IncomeJYNT's net income from continuing operations was well above estimates due to significantly lower-than-expected operating expenses.
Bears Say
Revenue GrowthJYNT's reduced sales outlook and weakening revenue growth reflect mounting headwinds in patient acquisition and a deliberate slowdown in clinic expansion.
Sales PerformanceSystem-wide comparable sales declined by 2.0%, below prior guidance, indicating potential challenges in sales performance.
Unit GrowthThe pace of refranchising appears to be slowing new openings, limiting near-term unit growth.
Joint News
JYNT FAQ
What was Joint Corp’s price range in the past 12 months?
Joint Corp lowest stock price was $7.50 and its highest was $13.47 in the past 12 months.
What is Joint Corp’s market cap?
Joint Corp’s market cap is $125.77M.
When is Joint Corp’s upcoming earnings report date?
Joint Corp’s upcoming earnings report date is Mar 05, 2026 which is in 102 days.
How were Joint Corp’s earnings last quarter?
Joint Corp released its earnings results on Nov 06, 2025. The company reported $0.02 earnings per share for the quarter, the consensus estimate of $0.02 by $0.
Is Joint Corp overvalued?
According to Wall Street analysts Joint Corp’s price is currently Undervalued.
Does Joint Corp pay dividends?
Joint Corp does not currently pay dividends.
What is Joint Corp’s EPS estimate?
Joint Corp’s EPS estimate is 0.04.
How many shares outstanding does Joint Corp have?
Joint Corp has 14,866,192 shares outstanding.
What happened to Joint Corp’s price movement after its last earnings report?
Joint Corp reported an EPS of $0.02 in its last earnings report, expectations of $0.02. Following the earnings report the stock price went down -3.885%.
Which hedge fund is a major shareholder of Joint Corp?
Currently, no hedge funds are holding shares in JYNT
Joint Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.33 (33.92% Upside)
$11.33 (33.92% Upside)
Blogger Sentiment
Neutral
JYNT Sentiment 50%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $104.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.87%
12-Months-Change
Fundamentals
Return on Equity
-1.37%
Trailing 12-Months
Asset Growth
-12.83%
Trailing 12-Months
Company Description
Joint Corp
Joint (JYNT) is a technology-driven health and wellness company focused on enhancing the quality of life through innovative products and services aimed at joint health. The company operates in the health supplements sector, providing a range of dietary supplements formulated to support joint function and mobility. Joint combines cutting-edge research with natural ingredients to create solutions that cater to both preventive health and therapeutic needs.
JYNT Company Deck
JYNT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive and negative aspects. The company showed growth in revenue and EBITDA, along with strong cash reserves and progress in refranchising. However, challenges such as declining sales metrics and revised guidance due to economic headwinds were noted.View all JYNT earnings summariesJYNT Stock 12 Month Forecast
Average Price Target
$11.33
▲(33.92% Upside)
Technical Analysis
National Healthcare
―
ModivCare
―
US Physical Therapy
―
Astrana Health
―
Oncology Institute
―
Ownership Overview
2.15% Insiders
13.83% Mutual Funds
46.13% Other Institutional Investors
28.49% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---